In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Francois Mach
Speaker
Francois Mach
Francois Mach Francois Mach

Geneva University Hospitals, Geneva (Switzerland)

Specialities : Risk Factors and Prevention , Acute Coronary Syndromes, Basic Science

Prof. François Mach (h index >50), born in 1961, is an expert in the field of cardiology, in particular with regard to the development and progression of atherosclerosis diseases. After obtaining his MD at the University of Geneva, Switzerland, he studied internal medicine and cardiology at Geneva University Hospital. He then went on to complete a post-doctoral fellowship in the laboratory of Prof. Peter Libby, Brigham and Women’s Hospital, Boston (1995-1999). Following his return to Switzerland in 2000, he became full Professor of cardiology, and in 2006 he was appointed Head of the cardiology department at Geneva University Hospital. Between 2012-14, he was the President of the Swiss Society of Cardiology. François Mach is the author of more than 400 high impact factor publications, has obtained several European research grants (“European Vascular Genomic Network” [EVGN] FP6, “Inflammation and Vascular Wall Remodelling in Atherosclerosis” [AtheroRemo] FP7), and is currently involved

27 presentations from this speaker

2019 ESC/EAS dyslipidaemia guidelines: recommendations for intensification of treatment.

Event : ESC Congress 2020

  • Session : Managing patients with dyslipidaemia: how to tackle clinical inertia
  • Speaker : F Mach (Geneva,CH)
  • Sponsored by Sanofi

Clinical relevance of the updates guidelines.

Event : EAPC Essentials 4 You 2020

  • Session : Updated ESC/EAS Dyslipidaemia Guidelines Webinar
  • Speaker : U Laufs (Leipzig,DE), F Mach (Geneva,CH)
  • Organised by AMGEN

Deep dive into 2019 ESC-EAS dyslipidaemia target.

Event : EAPC Essentials 4 You 2020

  • Session : Updated ESC/EAS Dyslipidaemia Guidelines Webinar
  • Speaker : F Mach (Geneva,CH)
  • Organised by AMGEN

Introduction to LDL-C and cardiovascular risk.

Event : EAPC Essentials 4 You 2020

  • Session : Updated ESC/EAS Dyslipidaemia Guidelines Webinar
  • Speaker : F Mach (Geneva,CH), U Laufs (Leipzig,DE)
  • Organised by AMGEN

Lifestyle modification in chronic coronary syndrome.

Event : ESC Congress 2020

  • Session : Chronic Coronary Syndrome - Essential Update
  • Speaker : F Mach (Geneva,CH)

One year after: what are the implications of the new The ESC/EAS LDL-c Guidelines for PCSK9i?

Event : ESC Congress 2020

  • Session : PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities
  • Speaker : F Mach (Geneva,CH)
  • Organised by PACE-CME, supported by Amgen and Sanofi in the form of an educational grant

Panel Discussion.

Event : ESC Congress 2020

  • Session : Managing patients with dyslipidaemia: how to tackle clinical inertia
  • Speaker : A Catapano (Milan,IT), JW Jukema (Leiden,NL), L Masana (Reus,ES), F Mach (Geneva,CH)
  • Sponsored by Sanofi

Welcome & Disclosure.

Event : EAPC Essentials 4 You 2020

  • Session : Updated ESC/EAS Dyslipidaemia Guidelines Webinar
  • Speaker : U Laufs (Leipzig,DE), F Mach (Geneva,CH)
  • Organised by AMGEN

What do the guidelines recommend for patients with ACS and why ?

Event : EAPC Essentials 4 You 2020

  • Session : Updated ESC/EAS Dyslipidaemia Guidelines Webinar
  • Speaker : F Mach (Geneva,CH), U Laufs (Leipzig,DE)
  • Organised by AMGEN

Achieving guideline-perfect LDL-C management

Event : ESC Congress 2019

  • Session : PCSK9 inhibitors: let’s get real
  • Speaker : KK Ray (London,GB), F Mach (Geneva,CH), A Vogt (Muenchen,DE)
  • Sponsored by Amgen Europe GmbH

Breaking news in dyslipidaemia guidelines – key changes in acute coronary syndromes management

Event : ESC Congress 2019

  • Session : The north face in acute coronary syndromes: let’s climb it!
  • Speaker : F Mach (Geneva,CH)
  • Sponsored by Amgen Europe GmbH

Latest insights into cholesterol management - Interactive questions and answers discussion

Event : ESC Congress 2019

  • Session : Latest insights into cholesterol management for the post-myocardial infarction patient
  • Speaker : F Mach (Geneva,CH), A Catapano (Milan,IT), D Atar (Oslo,NO)
  • Sponsored by MSD

Lipid lowering treatment for selected patient populations.

Event : ESC Congress 2019

  • Session : 2019 ESC/EAS Guidelines on Dyslipidaemias
  • Speaker : F Mach (Geneva,CH)

Most Recent ESC/EAS dyslipidemia guidelines

Event : ESC Congress 2019

  • Session : Latest insights into cholesterol management for the post-myocardial infarction patient
  • Speaker : F Mach (Geneva,CH)
  • Sponsored by MSD

Panel discussion and closing remarks

Event : ESC Congress 2019

  • Session : The north face in acute coronary syndromes: let’s climb it!
  • Speaker : M Sabatine (Boston,US), F Mach (Geneva,CH), GM De Ferrari (Pavia,IT), KC Koskinas (Bern,CH)
  • Sponsored by Amgen Europe GmbH

PCSK9 inhibitors - Panel discussion and close

Event : ESC Congress 2019

  • Session : PCSK9 inhibitors: let’s get real
  • Speaker : KK Ray (London,GB), JR Gonzalez Juanatey (Santiago De Compostela,ES), F Mach (Geneva,CH), A Vogt (Muenchen,DE)
  • Sponsored by Amgen Europe GmbH

PCSK9 inhibitors in my practice.

Event : ESC Congress 2019

  • Session : How to implement PCSK9 inhibitor treatment in my practice
  • Speaker : F Mach (Geneva,CH)

PCSK9 inhibitors: let’s get real

Event : ESC Congress 2019

  • Session : PCSK9 inhibitors: let’s get real
  • Speaker : JR Gonzalez Juanatey (Santiago De Compostela,ES), F Mach (Geneva,CH), A Vogt (Muenchen,DE)
  • Sponsored by Amgen Europe GmbH

Side effects of statins: conjecture vs evidence.

Event : ESC Congress 2019

  • Session : Evolving concepts in lipidology
  • Speaker : F Mach (Geneva,CH)

The north face in acute coronary syndromes: let’s climb it

Event : ESC Congress 2019

  • Session : The north face in acute coronary syndromes: let’s climb it!
  • Speaker : GM De Ferrari (Pavia,IT), KC Koskinas (Bern,CH), F Mach (Geneva,CH)
  • Sponsored by Amgen Europe GmbH

Audience question and answer session.

Event : ESC Congress 2018

  • Session : Precision medicine in coronary patients: enhanced risk identification and treatment
  • Speaker : GM De Ferrari (Pavia,IT), M Bonaca (Boston,US), F Mach (Geneva,CH)
  • Sponsored by MSD

Innovative strategies for lipid lowering treatment: PCSK9 inhibition

Event : ESC Congress 2018

  • Session : Innovative strategies for secondary prevention
  • Speaker : F Mach (Geneva,CH)

Latest insight into risk identification and potential implications for futuretreatment standards.

Event : ESC Congress 2018

  • Session : Precision medicine in coronary patients: enhanced risk identification and treatment
  • Speaker : M Bonaca (Boston,US), F Mach (Geneva,CH)
  • Sponsored by MSD

Audience Q&A - State-of-the-art-lipid treatment in coronary patients in 2017.

Event : ESC Congress 2017

  • Session : State-of-the-art lipid treatment in coronary patients in 2017
  • Speaker : M Bonaca (Boston,US), E Braunwald (Boston,US), F Mach (Geneva,CH)
  • Sponsored by MSD

New strategies for lipid lowering in patients after STEMI: ready for prime time?

Event : ESC Congress 2017

  • Session : Pharmacotherapy after STEMI: current concepts
  • Speaker : F Mach (Geneva,CH)

Positioning of the topic - The PCSK9 story .. so far

Event : ESC Congress 2017

  • Session : Do we need PCSK9 inhibitors in post-MI patients?
  • Speaker : F Mach (Geneva,CH)

State-of-the-art lipid-lowering combination therapies.

Event : ESC Congress 2017

  • Session : State-of-the-art lipid treatment in coronary patients in 2017
  • Speaker : F Mach (Geneva,CH)
  • Sponsored by MSD

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are